Volume 66, Issue 6, Pages (December 2014)

Slides:

Advertisements

Similar presentations

Early Detection of Prostate Cancer in 2007

Advertisements

Volume 56, Issue 5, Pages (November 2009)

Volume 55, Issue 1, Pages 1-8 (January 2009)

Volume 72, Issue 1, Pages (July 2017)

Volume 54, Issue 2, Pages (August 2008)

Volume 68, Issue 2, Pages (August 2015)

Volume 57, Issue 1, Pages (January 2010)

Volume 50, Issue 1, Pages (July 2006)

Volume 52, Issue 1, Pages (July 2007)

Volume 51, Issue 2, Pages (February 2007)

Volume 62, Issue 5, Pages (November 2012)

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Volume 59, Issue 1, Pages (January 2011)

Testosterone Therapy in Men With Prostate Cancer

Volume 56, Issue 6, Pages (December 2009)

Volume 64, Issue 1, Pages (July 2013)

Volume 61, Issue 6, Pages (June 2012)

Volume 64, Issue 6, Pages (December 2013)

Volume 61, Issue 5, Pages (May 2012)

Volume 73, Issue 6, Pages (June 2018)

Volume 53, Issue 5, Pages (May 2008)

Volume 61, Issue 2, Pages (February 2012)

Prostate Cancer Epidemic in Sight?

Volume 61, Issue 3, Pages (March 2012)

Volume 63, Issue 4, Pages (April 2013)

The Global Risk of Bladder Cancer: Let's Just Do Something About It!

Volume 54, Issue 4, Pages (October 2008)

Elizabeth K. Bancroft, Rosalind A. Eeles

Prostate Cancer Risk Assessment in Biopsy-naïve Patients: The Rotterdam Prostate Cancer Risk Calculator in Multiparametric Magnetic Resonance Imaging-Transrectal.

Prostate Cancer Detection: A View of the Future

Ongoing Gleason Grade Migration in Localized Prostate Cancer and Implications for Use of Active Surveillance Adam B. Weiner, Ruth Etzioni, Scott E. Eggener

Volume 54, Issue 5, Pages (November 2008)

Volume 56, Issue 2, Pages (August 2009)

Volume 66, Issue 3, Pages (September 2014)

Counselling the Prostate Cancer Patient

Prostate Cancer Epidemic in Sight?

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Volume 68, Issue 6, Pages (December 2015)

Volume 61, Issue 6, Pages (June 2012)

Volume 66, Issue 2, Pages (August 2014)

Shifting Paradigms for High-grade Prostatic Intraepithelial Neoplasia

Volume 71, Issue 1, Pages (January 2017)

Volume 63, Issue 3, Pages (March 2013)

Volume 65, Issue 6, Pages (June 2014)

Volume 64, Issue 1, Pages (July 2013)

Volume 68, Issue 4, Pages (October 2015)

Is It Necessary to Detect All Prostate Cancers in Men with Serum PSA Levels

Volume 48, Issue 6, Pages (December 2005)

Volume 64, Issue 4, Pages (October 2013)

Volume 50, Issue 5, Pages (November 2006)

CyberKnife in the Treatment of Prostate Cancer: A Revolutionary System

Volume 55, Issue 3, Pages (March 2009)

Testicular Cancer Variations in Time and Space in Europe

Volume 54, Issue 6, Pages (December 2008)

Volume 59, Issue 4, Pages (April 2011)

Volume 72, Issue 1, Pages (July 2017)

European Urology is “Your” Journal

Jonathan S. Brajtbord, Michael S. Leapman, Matthew R. Cooperberg

Thomas Steuber, Matthew Frank O'Brien, Hans Lilja European Urology

Prostate Cancer Screening Decreases the Absolute Risk of Being Diagnosed with Advanced Prostate Cancer—Results from a Prospective, Population-Based Randomized.

Volume 52, Issue 6, Pages (December 2007)

Volume 68, Issue 2, Pages (August 2015)

Edith Canby-Hagino, Javier Hernandez, Timothy C. Brand, Ian Thompson

Volume 53, Issue 2, Pages (February 2008)

Volume 74, Issue 6, Pages (December 2018)

Volume 51, Issue 2, Pages (February 2007)

Volume 54, Issue 3, Pages (September 2008)

Oncoforum Urology: Prostate Cancer 2008 at a Glance

Volume 52, Issue 5, Pages (November 2007)

Assessing a Patient’s Individual Risk of Biopsy-detectable Prostate Cancer: Be Aware of Case Mix Heterogeneity and A Priori Likelihood Jan F.M. Verbeek,

Presentation transcript:

Volume 66, Issue 6, Pages 1109-1115 (December 2014) The Added Value of Percentage of Free to Total Prostate-specific Antigen, PCA3, and a Kallikrein Panel to the ERSPC Risk Calculator for Prostate Cancer in Prescreened Men Moniek M. Vedder, Esther W. de Bekker-Grob, Hans G. Lilja, Andrew J. Vickers, Geert J.L.H. van Leenders, Ewout W. Steyerberg, Monique J. Roobol European Urology Volume 66, Issue 6, Pages 1109-1115 (December 2014) DOI: 10.1016/j.eururo.2014.08.011 Copyright © 2014 Terms and Conditions

Fig. 1 Net benefit of prediction models with prostate cancer antigen 3 and/or the kallikrein panel in the subgroup of men with prostate-specific antigen ≥3.0 ng/ml (n=202). k-panel=kallikrein panel; PCA3=prostate cancer antigen 3; RC=risk calculator. European Urology 2014 66, 1109-1115DOI: (10.1016/j.eururo.2014.08.011) Copyright © 2014 Terms and Conditions

Fig. 2 Net benefit of prediction models with prostate cancer antigen 3 and/or the kallikrein panel in all men (n=708). k-panel=kallikrein panel; PCA3=prostate cancer antigen 3; RC=risk calculator. European Urology 2014 66, 1109-1115DOI: (10.1016/j.eururo.2014.08.011) Copyright © 2014 Terms and Conditions